What's Going On With Aardvark Therapeutics Stock On Wednesday?

Benzinga_recent_news03-04 21:54

Aardvark Therapeutics Inc. (NASDAQ:AARD) on Monday announced to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome. The update has sent the stock plunge almost 61%. The decision comes ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616552895?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-03-04 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616552895","market":"hk","top_or_hot":-1,"title":"What's Going On With Aardvark Therapeutics Stock On Wednesday?","media":"Benzinga_recent_news","content":"<div>\n<p>Aardvark Therapeutics Inc. (NASDAQ:AARD) on Monday announced to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\nThe update has sent the stock plunge almost 61%. The decision comes ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What's Going On With Aardvark Therapeutics Stock On Wednesday?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat's Going On With Aardvark Therapeutics Stock On Wednesday?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-04 21:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aardvark Therapeutics Inc. (NASDAQ:AARD) on Monday announced to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\nThe update has sent the stock plunge almost 61%. The decision comes ...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMA","symbol_name":"Smartstop Self Storage REIT Inc","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday","article_id":"2616552895","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/Pipette-Adding-Fluid-To-One-Of-Several-T.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51033235/whats-going-on-with-aardvark-therapeutics-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616552895","pubTimestamp":1772632440,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aardvark Therapeutics pauses Phase 3 HERO trial after cardiac safety observations, sending shares down nearly 61%.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMA":"Smartstop Self Storage REIT Inc","BK4217":"自存仓储房地产信托","AARD":"Aardvark Therapeutics"},"translate_title":"周三Aardvark Therapeutics股票走势如何？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AARD":1.5,"SMA":1},"content_text":"Aardvark Therapeutics Inc. (NASDAQ:AARD) on Monday announced to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.\nThe update has sent the stock plunge almost 61%. The decision comes as the company is conducting a comprehensive review of safety data.\nThe company revealed that it will not announce topline data from the HERO trial as previously anticipated in the third quarter of 2026 due to reversible cardiac observations at higher than target therapeutic doses found during routine safety monitoring.\nWilliam Blair analyst Andy Hsieh noted that the severe disruption of the study pause may prevent the ongoing Phase 3 HERO trial from being fully completed, but it opens the possibility of unblinding the study early.\nThe CEO, Tien Lee, emphasized the commitment to patient safety and the importance of evaluating the signals seen at elevated doses of ARD-101. \nThe company plans to continue collaborating closely with the FDA and the Prader-Willi Syndrome community while determining the next steps for its clinical program.\nThe stock is currently trading 1.5% below its 20-day simple moving average (SMA) and 2.3% below its 100-day SMA, indicating a bearish trend in the short to medium term. \nShares have decreased approximately 73% over the past 12 months and are currently positioned closer to their 52-week lows than highs.\nThe RSI is at 50.00, which is considered neutral territory. Meanwhile, MACD is at -0.05, below its signal line at 0.00, indicating bearish pressure on the stock.\nThe combination of neutral RSI and bearish MACD suggests mixed momentum.\nAnalyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $21.89. Recent analyst moves include:\nAARD Price Action: Aardvark Therapeutics shares were up 0.09% at $4.91 during premarket trading on Wednesday, according to Benzinga Pro data.\nPhoto by motorolka via Shutterstock\nThis content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.\nTo add Benzinga News as your preferred source on Google, click here.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616552895","isCrawlerRequest":true}